COPD Treatment Update

The UK will witness an increase in Chronic Obstructive Pulmonary Disease (COPD) in the near future, with the corresponding therapy market demonstrating greater revenue growth as a result

The firm's latest report* forecasts COPD prevalence in the UK will climb from 2.3 million in 2012 to 2.8 million in 2019, while other major European countries, including Germany, France, Italy and Spain, are anticipated to experience relatively stable patient figures.

Correspondingly, the UK's COPD therapeutics market value is expected to outperform its European competitors in terms of growth, with revenue climbing from $483m in 2012 to $855m in 2019 at a Compound Annual Growth Rate (CAGR) of 8.5%.

The disease is the fifth-leading cause of death in the world is a progressive disorder associated with chronic inflammation of the airways and lungs.

The authors believe the UK's steadily rising COPD prevalence could be attributed to greater awareness and diagnosis of COPD amongst younger people. The early stages of COPD often go undiagnosed, resulting in low diagnosis rates, but this is expected to improve across the UK in the following decade.

The global COPD therapeutics market will be driven by the entry of new, more efficacious and convenient products over the coming years. Upcoming combination drugs including Novartis's QVA-149, GSK's umeclidinium bromide/vilanterol and Boehringer Ingelheim's olodaterol/tiotropium promise greater efficacy than their individual components and currently available treatments, and the continued growth of the industry will rely largely on their success.

The new report states that much of the unmet need associated with COPD can be linked to poor treatment adherence. Accordingly, current drug development programs are focusing on producing long-acting, once-daily medications that offer greater convenience over many current treatments that require more frequent dosages.

This report provides detailed analysis of the COPD pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The COPD clinical trial landscape is then analysed, with a particular emphasis on failure rates across phases as well as the trends in clinical trial size and duration and by mechanism of action.

9 Replies

oldestnewest
  • what source does this come from martin? Can you provide the link please?

  • thanks martin

  • Interesting read.

    Lynne xx

  • Very intersting. Thank you.

    I've just found out that my Seretide inhaler costs £60!

    Good grief, I knew they were expensive but that much? No wonder cons. was pushing the Accuhaler which is considerably cheaper.

    Billions more to be made on pulmonary meds so hopefully they're working hard on better treatments/research.

  • hi martin,good read.ye if I had been diagonised instead of being fobbed of by ex gp /with xrays ok carry on/I wouldn't be as bad,and yes more awareness now,wen I told my dayghters they asked wat is copd mum.yes id never heard of it either,they was ready to go to see gp they was that mad at him just fobbing me of with ur ok nothing there,and its not all down to smoking either,in the market 4week ago was 2 blf nurses giving out spimetry tests and 37ppl has it,they didn't have a clue wat it was,was told see gp as they are past mild copd way past,so drug companies be clapping there hands and counting the pound signs for many years to come,instead of finding a cure ,makes me sik,whoever does find it will be a trillionare thousands of times over,we live in hope,take care

  • this country as lagged behind for years with treatments for us,but are willing to send hundreds of thousands of money aid overseas,need to stop and see to this country 1st ,like many medics say to ppl if u cant afford a family why have a big 1,should say that to overseas ppl.and why have babies overseas wen they no will be born with aids ridiculous,should offer them free sterilization and the men /ive no time for it now,none of it

  • I don't think its a question of either/or caroll. And I would think carefully before judging radically different cultures.

    The question has nothing to do with your answer.

  • hi hypercat,ive just read ur reply sorry its late reply its the new site plays up some time,i never judge different cultures,im not English fully,my children are half English my grandchildren are mixed alf red indian half Asian and half black ,I do think carefully at all times,i have lived abroad in countries were ive seen 1st hand were the money gos and its not to the ppl who need it most,inshallah.

You may also like...